Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods.
Ramsenthaler C et al. Qual Life Res. 2017 Jul 27. doi: 10.1007/s11136-017-1660-z. [Epub ahead of print].

The Experience of Myeloma Caregivers During Home-Based Oral Chemotherapy Treatment: A Qualitative Study.
Morris M et al. Semin Oncol Nurs. 2017 Jul 24. pii: S0749-2081(17)30045-1. doi: 10.1016/j.soncn.2017.05.010. [Epub ahead of print].

Immunotherapy in Multiple Myeloma.
Gleason C et al. Semin Oncol Nurs. 2017 Jul 24. pii: S0749-2081(17)30046-3. doi: 10.1016/j.soncn.2017.05.011. [Epub ahead of print].

Active multiple myeloma suppresses and typically eliminates coexisting MGUS.
Campbell JP et al. Br J Cancer. 2017 Jul 20. doi: 10.1038/bjc.2017.229. [Epub ahead of print].

Plasma Cell Myeloma in Children and Young Adults: A Report of 4 Cases From a Single Institution and a Review of the Literature.
Yohe S et al. J Pediatr Hematol Oncol. 2017 Jul 17. doi: 10.1097/MPH.0000000000000907. [Epub ahead of print].

Young Adults with Multiple Myeloma.
Devine H et al. Semin Oncol Nurs. 2017 Jul 13. pii: S0749-2081(17)30042-6. doi: 10.1016/j.soncn.2017.05.007. [Epub ahead of print].

Patient Reported Outcomes in Optimizing Myeloma Patients’ Health-Related Quality of Life.
King TA et al. Semin Oncol Nurs. 2017 Jul 12. pii: S0749-2081(17)30041-4. doi: 10.1016/j.soncn.2017.05.006. [Epub ahead of print].

Systematic Review and Network Meta-Analysis of Treatment Outcomes for Multiple Myeloma.
Armoiry X et al. J Clin Oncol. 2017 Jul 12:JCO2017731828. doi: 10.1200/JCO.2017.73.1828. [Epub ahead of print].

Living with hematologic cancer: Recommendations, solutions.
Faiman B et al. Cleve Clin J Med. 2017 Jul;84(7):528-534. doi: 10.3949/ccjm.84a.15159.

How I treat first relapse of myeloma.
Harousseau JL et al. Blood. 2017 Jul 5. pii: blood-2017-03-726703. doi: 10.1182/blood-2017-03-726703. [Epub ahead of print].

The therapeutic potential of cell cycle targeting in multiple myeloma.
Maes A et al. Oncotarget. 2017 Jun 28. doi: 10.18632/oncotarget.18765. [Epub ahead of print].

Guidelines for the use of imaging in the management of patients with myeloma.
Chantry A et al. Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14827. [Epub ahead of print].

M-protein-negative Myeloma Mimicking Lumbar Disc Herniation.
Hirota Y et al. Intern Med. 2017;56(13):1725-1727. doi: 10.2169/internalmedicine.56.8158. Epub 2017 Jul 1.

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.
Mohyuddin GR et al. Leuk Lymphoma. 2017 Jul 3:1-4. doi: 10.1080/10428194.2017.1344906. [Epub ahead of print].

Standardisation of minimal residual disease in multiple myeloma.
Innao V et al. Eur J Cancer Care (Engl). 2017 Jul 3. doi: 10.1111/ecc.12732. [Epub ahead of print].

The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers.
Oberoi D et al. Support Care Cancer. 2017 Jun 30. doi: 10.1007/s00520-017-3766-9. [Epub ahead of print].

New drugs in myeloma: beware of phase I trial results, beware of cost and demand for new trials.
Moreau P. Leukemia. 2017 Jun 30. doi: 10.1038/leu.2017.188. [Epub ahead of print].

Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies.
Li Y et al. J Viral Hepat. 2017 Jun 28. doi: 10.1111/jvh.12742. [Epub ahead of print].

Drug Combinations with Transplantation for Myeloma.
Baer D. N Engl J Med. 2017 Jul 6;377(1):92-3. doi: 10.1056/NEJMc1705671.

Melphalan hydrochloride for the treatment of multiple myeloma.
Esma F et al. Expert Opin Pharmacother. 2017 Aug;18(11):1127-1136. doi: 10.1080/14656566.2017.1349102. Epub 2017 Jul 10.

Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry.
Andersen KT et al. Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24857. [Epub ahead of print].

Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome.
Santiago V et al. Leuk Lymphoma. 2017 Jul 21:1-9. doi: 10.1080/10428194.2017.1352094. [Epub ahead of print].

Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents.
Tremblay D et al. Bone Marrow Transplant. 2017 Jul 24. doi: 10.1038/bmt.2017.160. [Epub ahead of print].

How I treat: New agents in myeloma.
Moreau P. Blood. 2017 Jul 26. pii: blood-2017-05-743203. doi: 10.1182/blood-2017-05-743203. [Epub ahead of print].

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.
Fouquet G et al. Leuk Lymphoma. 2017 Jul 12:1-7. doi: 10.1080/10428194.2017.1339876. [Epub ahead of print].